Cargando…
P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429691/ http://dx.doi.org/10.1097/01.HS9.0000849800.15938.16 |
| _version_ | 1784779537659199488 |
|---|---|
| author | Russell-Smith, A. Shah, R. Silverstein, A. Petrilla, A. Leinwand, B. Norris, D. Schroeder, A. |
| author_facet | Russell-Smith, A. Shah, R. Silverstein, A. Petrilla, A. Leinwand, B. Norris, D. Schroeder, A. |
| author_sort | Russell-Smith, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9429691 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94296912022-08-31 P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA Russell-Smith, A. Shah, R. Silverstein, A. Petrilla, A. Leinwand, B. Norris, D. Schroeder, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9429691/ http://dx.doi.org/10.1097/01.HS9.0000849800.15938.16 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Russell-Smith, A. Shah, R. Silverstein, A. Petrilla, A. Leinwand, B. Norris, D. Schroeder, A. P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title | P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_full | P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_fullStr | P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_full_unstemmed | P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_short | P1736: CHARACTERISTICS, HEALTHCARE UTILIZATION, AND COSTS ASSOCIATED WITH INOTUZUMAB OZOGAMICIN, BLINATUMOMAB, OR OTHER AGENTS FOR THE TREATMENT OF RELAPSED/REFRACTORY ACUTE LYMPHOBLASTIC LEUKEMIA |
| title_sort | p1736: characteristics, healthcare utilization, and costs associated with inotuzumab ozogamicin, blinatumomab, or other agents for the treatment of relapsed/refractory acute lymphoblastic leukemia |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429691/ http://dx.doi.org/10.1097/01.HS9.0000849800.15938.16 |
| work_keys_str_mv | AT russellsmitha p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT shahr p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT silversteina p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT petrillaa p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT leinwandb p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT norrisd p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia AT schroedera p1736characteristicshealthcareutilizationandcostsassociatedwithinotuzumabozogamicinblinatumomaborotheragentsforthetreatmentofrelapsedrefractoryacutelymphoblasticleukemia |